Psychedelics or SSRI's?

This new research looks at the effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder.

The study found that six-week intensive treatments with either psilocybin or escitalopram (with psychological support) for MDD were associated with long-term improvements in depressive symptom severity. The greater degree of improvement in the PT arm at follow-up on psychosocial functioning, meaning in life, and psychological connectedness suggests warrant future research.

Read more

Psilocybin for Inner Healing Depression

The journey to healing from depression often demands more than just symptom management; it requires a deep, inner transformation that addresses the root of emotional distress.

This inner healing process is crucial for those suffering from depression, as it can lead to more profound and lasting recovery.

Emerging research on psychedelics, particularly psilocybin, is shedding light on how these substances might facilitate this essential aspect of healing, offering new hope for individuals struggling with depression.

Read more

Promising Results for Depression Treatment with Microdosing LSD

MindBio Therapeutics Corp. (CSE) has recently unveiled promising durability data from its Phase 2A clinical trials, which tested MB22001, the company’s innovative self-administered, take-home microdose of Lysergic Acid Diethylamide (LSD), as a treatment for depression.

This development underscores MindBio’s commitment to advancing psychedelic medicine as a viable option for mental health treatment.

Read more

Three Studies of MDMA Treatment Retracted by Scientific Journal

The journal Psychopharmacology has retracted three papers about MDMA-assisted therapy based on what the publication said was unethical conduct at one of the study sites where the research took place.

Several of the papers’ authors are affiliated with Lykos Therapeutics, the drug company whose application for MDMA-assisted therapy to treat post-traumatic stress disorder was rejected last week by the Food and Drug Administration.

Read more

UC Berkeley’s Groundbreaking Study on Psilocybin

The UC Berkeley Center for the Science of Psychedelics has embarked on an unprecedented study to explore why psilocybin, a psychoactive compound found in certain mushrooms, alters visual perception in humans.

This investigation represents the university’s first human trials involving a Schedule I substance, classified by the federal government as having no accepted medical use.

Psilocybin, commonly known as “shrooms” or “magic mushrooms,” can significantly distort users’ sense of time, mood, and reality, often causing hallucinations.

Read more